Eli Lilly vs Novo Nordisk
- Dec 27, 2025
- 7 min read
Updated: Jan 18
The global obesity treatment market has become one of the most attractive and competitive areas in healthcare investing, driving unprecedented revenue growth, valuation expansion, and market attention.
At the heart of this transformation stand Eli Lilly and Novo Nordisk, two pharmaceutical leaders competing for dominance in a segment that could redefine long-term earnings power for the industry.
In this post, we will compare both businesses in depth, what they sell, how their growth trajectories differ, and why Eli Lilly continues to outperform while Novo Nordisk has recently struggled. We will analyze the obesity segment specifically, examining market share dynamics, product differentiation, and competitive positioning to understand how each company is capturing value in this rapidly expanding market.
Beyond operations, we will also focus on valuation. Despite its strong execution and market leadership, Eli Lilly currently trades at a premium valuation, leading many investors to question whether the stock is becoming overvalued. In contrast, Novo Nordisk has seen a shift in sentiment that has left some investors arguing the company may be undervalued.
We will explore why market perception has diverged so sharply, what risks and expectations are currently priced into each stock, and whether this gap is justified.
